News about "Combination Therapy "

Oliva Therapeutics to Commercially Launch Amerithroid for Hypothyroidism Treatment

Oliva Therapeutics to Commercially Launch Amerithroid for Hypothyroidism Treatment

Oliva Therapeutics is set to launch Amerithroid, a US-manufactured desiccated thyroid extract developed in partnership with Jerome Stevens Pharmaceuticals, strengthening its endocrine care portfolio with a naturally derived treatment for hypothyroidism.

Combination Therapy | 06/07/2026 | By News Bureau 110

Chugai Pharmaceutical Secures Global First Approval for Lunsumio' Polivy Combo in Relapsed Large B-Cell Lymphoma

Chugai Pharmaceutical Secures Global First Approval for Lunsumio' Polivy Combo in Relapsed Large B-Cell Lymphoma

Japan’s health ministry approves the first in world combination of Lunsumio and Polivy, showing strong response rates and reduced disease progression risk in relapsed or refractory lymphoma patients.

Combination Therapy | 24/03/2026 | By News Bureau 161

Chugai Pharmaceutical Secures Global First Approval for Lunsumio' Polivy Combo in Relapsed Large B-Cell Lymphoma

Chugai Pharmaceutical Secures Global First Approval for Lunsumio' Polivy Combo in Relapsed Large B-Cell Lymphoma

Japan’s health ministry approves the first in world combination of Lunsumio and Polivy, showing strong response rates and reduced disease progression risk in relapsed or refractory lymphoma patients.

Combination Therapy | 24/03/2026 | By News Bureau 161

Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer

Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer

Biotheryx advances BTX-9341 into a dose expansion trial with fulvestrant for HR+/HER2- breast cancer, aiming to overcome resistance in patients previously treated with CDK4/6 inhibitors.

Combination Therapy | 19/03/2026 | By News Bureau 162

Akeso and Inovio Pharmaceuticals Partner to Develop Combination Therapy for Glioblastoma

Akeso and Inovio Pharmaceuticals Partner to Develop Combination Therapy for Glioblastoma

Akeso and Inovio Pharmaceuticals have entered into a clinical collaboration to evaluate cadonilimab with INO-5412 in glioblastoma. The combination will be studied in the phase-II INSIGhT trial sponsored by Dana-Farber Cancer Institute, building on prior positive data.

Combination Therapy | 05/03/2026 | By Akanki 165


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members